Asia-Pacific cancer monoclonal antibodies market is estimated to grow at a CAGR of 11.2% during the forecast period. The significant prevalence of cancer and increasing launches of new monoclonal antibodies are some pivotal factors accelerating market growth. As per the World Health Organization (WHO), the number of new cancer incidences in China was nearly 4.3 million in 2018. Additionally, the number of new cancer incidences in India was nearly 1.1 million in 2018. Improving healthcare infrastructure and increasing awareness has led to the demand for novel cancer therapies in the region. This, in turn, is driving the demand for monoclonal antibodies that acts as a targeted therapy to better recognize and destroy cancer cells. Some monoclonal antibodies drugs launched in the region include Avastin biosimilar, Tecentriq, XGEVA (denosumab), and others. 

Visit for Global Cancer Monoclonal Antibodies Market Report at: https://www.omrglobal.com/industry-reports/cancer-monoclonal-antibodies-market

Asia-Pacific cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others. Monoclonal antibodies find significant application in breast cancer coupled with the rising incidences of breast cancer in the region. As per the WHO, in India, breast cancer accounted for 14.0% or 162,468, while in China, it accounted for 8.6% or 367,900 of all cancer types in 2018. Kadcyla, (also referred to as TDM-1) targets the HER2 protein like Herceptin. These therapies act against the HER2 protein as this protein is found in massive amounts on certain kinds of breast cancer cells. The therapy is utilized for the treatment of HER2-positive breast cancer. Most often monoclonal antibodies are combined with additional cancer-fighting drugs, including chemotherapy. 

Some prominent players in the market include Biocon Ltd., Amgen Inc., F. Hoffman La-Roche AG, Pfizer Inc., and Mylan N.V. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in October 2019, Amgen declared collaboration with BeiGene that will further widen Amgen's plans to enhance its oncology presence in China. Under the agreement, BeiGene will commercialize BLINCYTO (blinatumomab), XGEVA (denosumab), and KYPROLIS (carfilzomib) in China. This acquisition will enable Amgen to commercialize its non-oncology product portfolio in China. 

Research Methodology

The market study of the Asia-Pacific cancer monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Asia-Pacific Cancer Monoclonal Antibodies Market Research and Analysis by Type
2. Asia-Pacific Cancer Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the Asia-Pacific cancer monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Asia-Pacific cancer monoclonal antibodies market.
• Insights about market determinants which are stimulating the Asia-Pacific cancer monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.